期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 128, 期 3, 页码 485-494出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.07.010
关键词
Asthma; childhood asthma; asthma therapy; asthma statistics; asthma management; asthma guidelines; asthma disease management; inhaled corticosteroids; long-acting beta-adrenergic agonists; leukotriene receptor antagonists; omalizumab; asthma surveillance; asthma mortality; asthma hospitalizations; asthma exacerbations; asthma progression; personalized medicine; public health
资金
- Public Health Services [HR-16048, HL64288, HL 51834, AI-25496, HL081335, HL075416]
- Colorado Cancer, Cardiovascular and Pulmonary Disease Program
- National Institutes of Health (NIH) [1 UL1 RR025780]
- National Center for Research Resources (NCRR)
- NIH/National Heart, Lung, and Blood Institute (NHLBI)
- NHLBI Childhood Asthma Research and Education (CARE)
- NIH/NHLBI Asthma Clinical Research Network (ACRN)
- NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium
- GlaxoSmithKline
- NIH/NHLBI Asthma Net
- National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center
Over the past 20 years, there has been a concerted effort in the United States to reduce morbidity related to chronic disease, including asthma. Attention was initially directed toward asthma in response to the recognition that asthma mortality was increasing and that the burden of disease was significant. These efforts to address asthma mortality led to many new initiatives to develop clinical practice guidelines, implement the asthma guidelines into clinical practice, conduct research to fill the gaps in the guidelines, and continuously revise the asthma guidelines as more information became available. An assessment of our progress shows significant accomplishments in relation to reducing asthma mortality and hospitalizations. Consequently, we are now at a crossroads in asthma care. Although we have recognized some remarkable accomplishments in reducing asthma mortality and morbidity, the availability of new tools to monitor disease activity, including biomarkers and epigenetic markers, along with information technology systems to monitor asthma control hold some promise in identifying gaps in disease management. These advances should prompt the evolution of new strategies and new treatments to further reduce disease burden. It now becomes imperative to continue a focus on ways to further reduce the burden of asthma and prevent its onset. (J Allergy Clin Immunol 2011;128:485-94.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据